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A few precepts
● The outcome from the treatment of invasive fungal infections remains poor for many 
patient groups, despite the availability of new antifungal agents. 
● Combining agents offers the potential to improve response and reduce mortality. 
● This review sets out the case for the use of combination therapy and outlines the set-
tings where it has been shown to be of benefit and where further clinical study may well 
support evidence from in-vitro and animal studies. 
● The incorporation of this evidence in the current international guidelines for antifun-
gal therapy is also discussed, emphasising the consensus for the use of combined antifun-
gals in defined infections.
© 2012 ACIN. Published by Elsevier España, S.L. All rights reserved.
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Introduction
Invasive fungal infection continues to exact a high cost 
in terms of morbidity and mortality, despite considerable 
progress in diagnosis and therapy in the latter stages of the 
last century. Disseminated disease may result in respiratory 
failure, neurological impairment, or loss of vision, to name 
just a few of the more common complications, while the sur-
vival rate from invasive aspergillosis is less than 20% in some 
patient groups1. It is, therefore, not surprising that attempts 
have been made, over the years, to improve the outcome of 
therapy by combining existing antifungal agents.
A PubMed search using the terms “combination antifun-
gal therapy” produces a list of more than 10,000 papers, 
although the numbers appear to have plateaued over the last 
few years. Many of these are reports of in-vitro studies of 
agents unlikely ever to be used for treating human invasive 
fungal infections; but even searching for clinical reviews on 
this topic reveals more than 1500 articles, demonstrating the 
importance of this concept and the high level of interest in it.
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This essay will set out the case for the use of combina-
tion therapy, and outline the settings where it has been 
shown to be of benefit and where further clinical study 
may well support evidence from in-vitro and animal stud-
ies. It will not consider the strategy of combining an anti-
fungal drug with an immunomodulator, although a number 
of small studies have suggested that such therapy may 
improve outcome over antifungal therapy alone.
Why combine antifungal agents?
The main potential benefits of combination therapy are 
set out in Box 1. The prime goal is to improve response 
and reduce mortality. This would be the consequence 
of a positive interaction between the agents (synergy or 
addition in pharmacodynamic terms), but the addition of 
another agent might allow a dose reduction in another. 
This could be a very worthwhile outcome, given the toxic-
ity of some antifungal agents, particularly amphotericin B 
(AMB). The in-vitro and animal model evidence for these 
scenarios will be discussed in more detail later.
Elsewhere in infectious diseases management, the most 
impressive examples of combination antimicrobial therapy 
producing improvements in outcome have been with anti-
tuberculous and anti-retroviral therapy. Here, using agents 
with different mechanisms of action preserves the efficacy 
of others by preventing the emergence of resistance during 
treatment. This is particularly important during the early 
phase of therapy where high organism numbers make even 
low resistance mutation rates liable to lead to the selec-
tion of resistant organisms. The use of flucytosine (5FC) 
alone has been shown to result in the rapid emergence of 
resistance during therapy of both Candida and Cryptococcus 
infection2 and its value as an anti-yeast drug is preserved by 
combining it with another suitable anti-yeast agent.
Emergence of resistance to treatment appears to be 
less of an issue with other antifungal agents, although 
obtaining isolates during therapy from deep infection 
sites is uncommon and so it is possible that some clini-
cal failures are due to selection of resistant organisms. 
Development of azole resistance during long term therapy 
of chronic pulmonary aspergillosis is well documented3. 
Combination therapy might, conceivably, prevent this, but 
there are very few oral options and the strategy has not 
been tested in the clinical setting.
Is combining antifungal agents plausible?
The question is: do the antifungal agents available for 
invasive infections have appropriate mechanisms of action 
likely to have a positive benefit if they are combined? In 
fact, there are a number of potential mechanisms for posi-
tive interaction and these have been extensively reviewed 
by Johnson and colleagues4.
Amphotericin B increases the permeability of fungal 
cell membranes which might facilitate the penetration of 
5FC5. This is likely to have a benefit in the treatment of 
fungi with known susceptibility to 5FC, such as Candida 
species or Cryptococcus neoformans, but it is possible that 
allowing higher intra-cellular levels of 5FC might have a 
positive therapeutic effect in fungal infections caused 
by species considered less susceptible to 5FC, such as 
Aspergillus species.
The inhibition of an additional stage of a common biochem-
ical pathway is likely to result in a further reduction of the end 
product. Hence the combination of terbinafine and an azole, 
acting on squalene epoxidase and lanosterol 14-demethylase, 
respectively, at different stages of the ergosterol synthetic 
pathway, should result in a positive interaction.
Inhibition of efflux transport mechanisms by one agent 
might increase the intracellular levels of another. Johnson 
has proposed this mechanism for the added benefit of AMB, 
blocking the efflux of 5FC when the two are combined4.
Targeting of independent sites or receptors is also likely 
to have a beneficial effect and this has been proposed as 
the mechanism for a positive interaction between azoles 
or AMB (acting on the cell membrane) and the echinocand-
ins (acting on the cell wall).
It is also possible that an agent with a rapid kill rate 
could be followed by another with fungistatic activity, 
once the fungal burden had been reduced4. Hence sequen-
tial combination therapy might facilitate therapy, even if 
the two agents were not acting simultaneously.
What is the evidence that combination 
antifungal therapy might be effective?
In-vitro data
The basis for combination antimicrobial therapy was origi-
nally established by in-vitro experiments, such as those 
demonstrating synergy between aminoglycosides and beta-
lactams. In-vitro testing of antifungal agents was ham-
pered for many years by lack of standardisation of sus-
ceptibility testing. Nevertheless, a number of drug-drug/
organism combinations have consistently been found to 
yield a positive benefit over the individual drugs alone, 
and this effect has been confirmed in several studies car-
ried out in the modern era of standardised testing.
Potential increased efficacy is demonstrated in the lab-
oratory or in animal models by synergy (the combination 
produces an effect greater than the sum of the activities 
of the individual agents), or addition (the effect is equal 
to the sum of the activities of the individual agents).Whilst 
the definitions of these may vary in different studies, the 
principles remain the same.
Traditionally, in-vitro interaction testing has taken the 
form of liquid or solid media experiments, examining the 
Table 1 The rationale for antimicrobial combination
Increased efficacy
↑ response rate
↓ mortality
Broadening the spectrum of cover
Reduction of toxicity (dose sparing)
Reduction in duration of therapy
Prevention of resistance
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impact on growth or via time-kill measurements. How-
ever, an understanding of the drug targets and the genetic 
basis for resistance is opening up the way for alternative 
approaches to screen for potentially beneficial drug com-
binations. The study of chemogenomics using gene deletion 
libraries of different fungi enables compounds conferring 
growth inhibition or cell death associated with particular 
genes or gene clusters to be identified. Different com-
pounds which inhibit strains with the same gene deletions 
may act on the same cellular pathways. Using bioinformat-
ics, compounds can be combined in-silico so that many 
potential combinations can be investigated without the 
expensive and time consuming laboratory work previously 
involved6. Promising paired chemogenetic profiles can then 
be studied by conventional in-vitro and animal models. This 
approach has revealed a number of new combinations with 
confirmed in-vitro synergistic effects, including against 
strains resistant to one of the pair, as well as confirming 
known synergistic or additive combinations6. One example 
is the combination of wortmannin with fluconazole (FLU) 
against FLU resistant strains of Candida albicans. Despite 
having extremely high MICs to FLU, the addition of wort-
mannin resulted in a strong cytotoxic effect6.
Hence, it is conceivable that the in-silico testing of new 
pairs of compounds may result in greatly enhanced activ-
ity, which can then be studied in animal models.
The logical combination of AMB plus 5FC against Cryp-
tococcus neoformans has produced variable results in early 
studies. However, those performed over the last twenty 
years have demonstrated synergy or indifference7-9. 
Schwarz and colleagues used several methods to study 
interactions against 30 clinical isolates of Cryptococcus 
neoformans and found synergy against 77% of the isolates 
using a checker board technique, and consistent synergy 
by time kill studies at 72 hours9. Indeed, this effect has 
been shown to hold for some 5FC resistant isolates11.
Flucytosine and azole combinations have been found to 
be indifferent or synergistic in most studies. The findings 
are method-related, with studies using checker board tech-
niques demonstrating synergy for more than 60% of isolates, 
but time kill experiments only showing indifference9.
In-vitro studies using Candida species have found positive 
interactions most consistently for AMB plus 5FC11. In addition, 
benefits have been shown for isolates resistant to 5FC12.
Micafungin combined with FLU has demonstrated spe-
cies dependent synergy by the checkerboard method, with 
the greatest effect seen with Candida albicans13. A posi-
tive effect was seen with the less echinocandin suscepti-
ble C. parapsilosis strains, and the authors suggest that 
such a combination would be useful in infections caused 
by FLU less susceptible strains of this species. However, a 
number of other echinocandin/azole combination studies 
have found variable results. Of interest, sequential stud-
ies of an echinocandin (caspofungin or anidulafungin) fol-
lowed by voriconazole (VOR) or posaconazole have shown 
increased damage to Candida species biofilms when com-
pared with the individual agents alone14.
With MICs generally higher for most agents versus Aspergil-
lus species than for Candida, there is considerable interest in 
demonstrating a positive effect for antifungal combinations. 
AMB plus 5FC has shown synergy in earlier studies, but indif-
ference has been found in more recent ones. AMB plus echi-
nocandins have generally shown positive interactions, but 
are isolate and species dependent to some extent. Extended 
spectrum azoles have also generally shown a positive effect 
in combination with echinocandins. Perea and colleagues15 
found that a combination of caspofungin plus VOR was syner-
gistic in 86% of 48 clinical isolates of Aspergillus species (24 
were Aspergillus fumigatus). Likewise, caspofungin plus itra-
conazole was synergistic against 30 of 31 clinical Aspergillus 
isolates using MIC endpoints16. Importantly, no evidence of 
antagonism was shown in these studies.
Of perhaps greater relevance is the fact that synergy 
with such combinations has been demonstrated against 
isolates with characterised resistance mechanisms. Hence, 
anidulafungin plus VOR was shown to be synergistic against 
8 of 10 G448S cyp51A VOR resistant mutants of Aspergillus 
fumigatus17. This suggests a role for combination therapy 
when samples are culture negative, but when the possibil-
ity of azole resistance exists and also a means of prevent-
ing the emergence of resistance on treatment – the exact 
situation in which combination therapy has advanced the 
treatment of tuberculosis and HIV infection.
In-vivo data
Animal models have many caveats, but they do provide the 
means for examining the efficacy of antifungal agents in 
eradicating an infection and allowing survival of the host, 
incorporating the many issues of pharmacokinetics versus 
pharmacodynamics which complicate the simple mecha-
nism of inhibiting or killing a fungus. The demonstration of 
positive interactions in-vivo is more likely to be relevant 
to human infection than laboratory data from experiments 
using non-physiological conditions.
Amphotericin B plus 5FC have been shown to prolong 
survival over the individual agents alone in a number 
of different animal models of cryptococcosis. Schwarz 
and colleagues demonstrated enhanced survival, as well 
as reduced fungal colony counts in the brain, lung and 
spleen, in a systemic mouse model18. A number of studies 
in mice have also shown a survival benefit and reduction 
in organ colony counts for combined 5FC and azoles. Thus, 
Allendoerfer found a reduction in brain colony counts with 
FLU plus 5FC, as well as a prolongation of survival19. How-
ever, the evidence for a positive effect with the combina-
tion of AMB plus an azole is mixed11.
In earlier studies, 5FC plus AMB have been shown to 
improve survival or reduce tissue counts of Candida species. 
Polak20,21 showed a benefit for the combination in mouse 
models and Thaler22 did likewise in neutropenic rabbits. 
More recently, in an immunosuppressed systemic Candida 
albicans mouse model, Hope and colleagues demonstrated 
enhanced reduction of fungal burden in the kidneys with 
this combination23.
However, combining 5FC with azoles has produced less 
clear-cut outcomes, with high dose FLU in combination 
producing strain dependent effects on survival in C. albi-
cans infected rabbits24.
Animal model studies of AMB plus FLU have again pro-
duced inconsistent results, with a rabbit endocarditis 
model showing that the combination was not superior to 
AMB alone, despite high dose FLU being used24. In mice, 
the combination was worse than AMB alone in terms of 
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survival and kidney fungal burden25. However, in a more 
recent immunocompromised mouse model, the combina-
tion was more effective than FLU alone, and at least as 
effective as the AMB component26. Interestingly, the same 
group subsequently showed no benefit for the combination 
of AMB and itraconazole in mice27.
Combinations of echinocandins with AMB have been 
studied using several different Candida species, including 
C. albicans28 and C. parapsilosis29, and all have shown a 
benefit, although the enhanced effect against C. parapsi-
losis was lost at higher doses of caspofungin29. Combining 
echinocandins with azoles in mice does not seem to add to 
the activity of the echinocandin alone30.
The combination of AMB with an azole has produced mixed 
results in different models of invasive aspergillosis, but, over-
all the effect has been one of indifference31. However, echi-
nocandin containing combinations have more often produced 
a positive effect than indifference and, importantly, they are 
not antagonistic. AMB plus caspofungin showed a reduction 
in kidney fungal burden over the individual drugs28, although 
others have shown no benefit in a central nervous system 
aspergillosis model in mice32, a setting in which neither drug 
penetrates well to the site of infection.
Azoles in combination with echinocandins have gener-
ally produced a positive effect, although the magnitude of 
this effect has varied in different studies. Kirkpatrick and 
colleagues found reduced tissue counts with the combina-
tion of VOR plus caspofungin, but no prolongation of sur-
vival in neutropenic guinea pigs33, whereas the addition of 
micafungin to ravuconazole in a neutropenic rabbit model 
reduced tissue fungal burden and increased survival over 
either drug alone34. Calvo and co-workers have recently 
shown that the addition of VOR to anidulafungin prolongs 
survival in mice infected with three strains of Aspergillus 
flavus, although there was only a significant benefit for 
one strain with the combination in comparison with VOR 
alone35. In addition, the combination had a significant 
impact on tissue colony counts in comparison with ani-
dulafungin, and was superior to VOR for one strain. It was 
noted that the combination was comparable with VOR in 
reducing galactomannan levels.
I have so far concentrated on the common invasive 
mycoses but there are infections caused by fungi which 
have high MICs to all the available systemic antifungals. 
Combination therapy offers the possibility of successful 
treatment, but is there evidence to support this approach?
One such infection is that caused by Scedosporium pro-
lificans which is becoming an increasing issue in Australia, 
the US and Southern Europe. In-vitro studies have shown 
positive interactions between VOR and terbinafine against 
this fungus36, and with echinocandins, azoles and AMB37. 
These interactions have been supported by in-vivo studies, 
including one of a recent murine model of disseminated 
infection caused by a clinical isolate of S. prolificans. The 
authors examined the double and triple interactions of 
AMB, VOR and micafungin and found that micafungin com-
bined with AMB or VOR significantly increased survival and 
reduced tissue counts in the brain and kidney. However, 
the triple combination gave no additional benefit.
It is unlikely that randomised comparative controlled 
trials of combination therapy for this uncommon infection 
will ever be conducted, but these studies point the way 
towards appropriate treatment, and the consensus for 
these novel therapies has now been established for this 
condition.
Are there consistent effects with particular 
organism-drug combination interactions?
One explanation for a lack of overall consistency in differ-
ent studies is the likelihood of concentration dependent 
effects. Hence, delivering the right concentration of each 
drug to the site of the infection may be crucial in achiev-
ing a beneficial effect. Using a response surface model, 
Meletiadis and co-workers have shown that the interaction 
of AMB, caspofungin and VOR is extremely complex and 
antagonism, as well as synergy, may be seen according to 
the relative concentrations of the different agents38.
However, a few antifungal combinations have consist-
ently shown positive interactions in both in-vitro and in-
vivo studies and these are summarised in Table 2. These 
have been the ones chosen for clinical trials, but the 
numbers of trials have been remarkably few. Most studies 
designed to demonstrate a benefit require the enrolment 
of hundreds of patients with proven or probable infection. 
This is a great challenge in the case of invasive aspergil-
losis (and much more so for the less common conditions 
such as Scedosporium prolificans infection, previously dis-
cussed), where even conducting trials of new single agents 
for licensing purposes has been extremely difficult.
What is the clinical evidence?
One of the earliest combination antifungal studies estab-
lished the role of AMB plus 5FC in the treatment of crypto-
coccosis in the pre-AIDS era39. This fulfilled a number of the 
objectives of combination therapy – increased response rate 
(although no survival benefit was shown), more rapid steri-
lisation of the cerebrospinal fluid and less toxicity – despite 
only enrolling 50 patients. Subsequent studies on HIV posi-
tive patients essentially confirmed this benefit. However, 
perhaps the most informative of these have studied the 
antifungal activity at the site of infection and demonstrated 
Table 2 Relative benefits of different antifungal 
combinations demonstrated by in-vitro and in-vivo studies
Infection Combination in-vitro in-vivo
Cryptococcosis Ampho + 5FC +++ +++ 
 Flucon + 5FC ++ ++
Invasive candidiasis Ampho + 5FC +++ +++ 
 Ampho + Flucon ± ++ 
 Flucon + 5FC ± ± 
 Echino + azoles + ± 
 Echino + Ampho + ++
Invasive aspergillosis Ampho + 5FC ++ ++ 
 Ampho + azoles ± ± 
 Echino + azoles ++ ++ 
 Echino + Ampho ++ ++
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convincing advantages for the AMB/5FC combination. A 
multi-national group based in Thailand used the concept 
of early fungicidal activity (the mean rate of fall in cer-
ebrospinal fluid log CFU counts) in patients treated in a 
randomised trial with different combinations of AMB, 5FC 
and FLU. The AMB plus 5FC combination was again supe-
rior to the others, and superior to the combination of all 
three40.
A systematic review of antifungal therapy for invasive 
candida infection has found no significant difference 
between the different agents in terms of all-cause mortal-
ity41. However, only two randomised trials of combina-
tion therapy were included: AMB plus FLU versus FLU42 
or VOR43. In the former, standard dose AMB) (0.7 mg/kg/
day) plus FLU (800 mg qd) produced a greater success rate 
by day 30 (the primary end point), although this was not 
significant (P=.08). However, the overall success rate was 
significantly greater in the combination arm (P=.043), and 
there were significantly fewer episodes with persistently 
positive blood cultures (6% vs 17%; P=.02), demonstrating 
the advantage of this approach in the more difficult to 
treat cases42.
The second study was a sequential, rather than a com-
bination one, but the persistence of the initial AMB is 
likely to have interacted with the subsequent FLU. How-
ever, at the 12 week primary end point there was no 
significant difference in the clinical and microbiological 
outcomes or in the percentage of patients with persistent 
blood cultures.
Hence there is inconsistent and rather sparse evidence 
to support the use of AMB plus FLU for invasive candida 
infection – rather like the in-vitro and animal data.
Unfortunately, the more promising AMB plus 5FC com-
bination has not been studied in large trials. A small pro-
spective randomised trial enrolled 72 patients to receive 
AMB (1.0-1.5 mg/kg/day) plus 5FC (2.5g tds) or FLU (400 
mg qd followed by 200 mg qd)44. While there was no 
significant difference in overall outcome, there was a sig-
nificant advantage for the combination in the treatment 
of peritonitis (55% vs 25% success), and in eradication of 
the pathogen (86% vs 50%). While the authors could be 
criticised for using lower FLU doses than currently used 
plus higher doses of AMB, more likely to cause nephrotox-
icity, the study does provide some support for the use of 
combination therapy for the more difficult to treat cases 
of invasive candida infection.
As already discussed, there have been few studies of 
combination therapy for invasive aspergillosis, and most 
of these have been retrospective. A review of more than 
6,000 cases of invasive aspergillosis included 249 treated 
with combination therapy45. The regimens were mostly an 
AMB product plus either 5FC, itraconazole or rifampicin, 
accounting for 91% of the total. The response rate was 64% 
and the mortality 34%, both high in comparison with con-
temporary and current data for monotherapy.
As noted in the previous sections, echinocandin-con-
taining combinations have shown considerable promise and 
a number of retrospective studies with historical controls 
have been published. A small study of 31 patients with 
haematological malignancies, with proven or probable 
invasive aspergillosis, and given initial therapy with AMB, 
investigated salvage therapy with VOR plus caspofungin46. 
There was a survival benefit (hazard ratio, 0.27; 95%CI, 
0.09–0.78; P=.008) in comparison with an historical control 
group of 16 patients given VOR only.
Several retrospective studies of caspofungin plus lipo-
somal AMB have shown good response rates (up to 75%) 
suggesting that echinocandin /AMB product combinations 
should be investigated further in prospective randomised 
trials47,48. The Combistrat trial has attempted to do just 
that in a small pilot study49. Thirty patients with proven or 
probable infection were randomised to receive AmBisome 
plus caspofungin or high dose (10mg/kg/day) Ambisome 
alone, with 67% vs 27% (P=.028) responding – similar to the 
response rates in the retrospective studies.
A much larger RCT of anidulafungin plus VOR versus 
VOR alone has recently completed50. On the face of it, 
this study appears to show no significant difference in 
outcome between the two arms. The mortality at week 
6 (the primary end point) in the combination arm was 
19.3% compared with 27.5% in the monotherapy arm 
– a relative risk reduction of 30%, but non-significant 
(P=.089). Unfortunately, out of the 454 patients enrolled, 
only 277 were able to be included in the modified inten-
tion to treat population for analysis, and this may have 
rendered the study numbers insufficient to demonstrate 
a true benefit. Of the 40% that were considered “not 
evaluable” by the Data Review Committee, 39 died in 
the monotherapy arm and 26 in the combination arm. 
This might well have biased the outcome of the study in 
favour of a non-significant result.
In fact, a subgroup analysis of those patients with posi-
tive galactomannan antigen assay results found that 15.7% 
of those treated with the combined regimen died by week 
6, versus 27.3% in the monotherapy arm, a significant 
reduction (P<.05). This suggests that those diagnosed by 
other means, who are, therefore, likely to have more 
advanced disease, are less likely to benefit from the com-
bination than those with a moderately severe infection. 
This is commensurate with the findings from the Rex can-
didaemia study42 where the benefit of the AMB plus FLU 
combination was greatest for those with an intermediate 
APACHE II score, in comparison with those with mild or 
severe severity of illness.
There was no difference in mortality between the dif-
ferent treatment groups in patients who had received an 
allogeneic stem cell transplant and those receiving other 
therapy. Importantly, this study showed no excess of 
treatment-related adverse events with the combination 
regimen. The majority of adverse events were considered 
to be related to VOR in both arms50.
Hence, overall, this trial showed that an echinocandin/
triazole combination is a safe treatment regimen, likely to 
improve outcome in moderately severe invasive aspergil-
losis in patients with haematological malignancies, the 
group with the highest mortality1.
What do the guidelines say?
The current guideline from the Infectious Diseases Society 
of America (IDSA) for the management of cryptococcosis 
recommends the combination of AMB plus 5FC for initial 
therapy of meningoencephalitis and for disseminated or 
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severe infection at other sites51. For HIV-positive patients, 
the World Health Organisation guidelines are very similar, 
again emphasising the benefit of combination therapy in 
this setting52.
The principle international guidelines for the manage-
ment of invasive candida infection are those of the IDSA53, 
the European Conference on Infection in Leukaemia (for 
patients with haematological malignancies)54, and the 
recent European Society of Clinical Microbiology and Infec-
tious Diseases Fungal Infection Study Group Diagnostic & 
Management Guideline for Candida Diseases 201155. There 
are, of course, a number of national guidelines providing 
recommendations on candida infection therapy.
The IDSA guidelines recommend monotherapy for almost 
all indications, but consider the combination of 5FC with 
an AMB product as primary therapy for central nervous 
system infections, candida endophthalmitis and endocar-
ditis, although all of these are based on evidence rated 
as level III: “Evidence from opinions of respected authori-
ties, based on clinical experience, descriptive studies, or 
reports of expert committees”53.
The European Conference on Infection in Leukaemia 
guidelines have made no recommendations on combina-
tion therapy for neutropenic patients, although it is noted 
that there is a paucity of data on candidaemia therapy in 
these patients54.
The Fungal Infection Study Group guidelines, again 
recommend monotherapy for the majority of indications, 
but, like the IDSA, consider combinations including 5FC as 
appropriate for central nervous system infections, endo-
carditis and endophthalmitis, with a moderate strength of 
recommendation and level of evidence55.
All the international guidelines dealing with the man-
agement of invasive aspergillosis, of course, pre-date the 
recently presented VOR/anidulafungin trial and so are 
based on relatively little evidence. The IDSA do not rec-
ommend combination therapy for routine primary therapy, 
but make a BII recommendation for unspecified combi-
nation therapy in the salvage setting56. The European 
Conference on Infection in Leukaemia guidelines likewise 
recommend against combination therapy for first line 
treatment, but rate as CII a recommendation of caspofun-
gin plus either VOR or a lipid–associated AMB product for 
salvage treatment. It will be interesting to see how the 
Marr study will impact on these recommendations.
Conclusions
This has been an article supporting the concept of com-
bination therapy in certain clinical settings and it has, 
therefore, been selective, to some extent, in citing data 
showing a positive benefit. The con debate will almost 
certainly do the opposite (perhaps even from within the 
same studies) and, of course, the truth lies somewhere in 
between these two extremes.
There is clearly variable evidence for improved effi-
cacy. We need to choose the settings where combination 
therapy is likely (and needed) to make a difference. These 
should be when there are infections with difficult to treat 
organisms and/or in certain anatomical sites, where evi-
dence suggests that combination will provide an improved 
outcome. We should not expect combination therapy to be 
a universal principle. There are relatively few indications 
for combining agents when treating bacterial and viral 
infections, and we must accept that the same goes for 
invasive fungal infections.
Differences in outcome with different animal models 
and with different strains of the same species suggest that 
PK/PD issues are extremely important for some combina-
tion/organism interactions. Optimisation of outcome may 
require more individualisation of therapy which could be 
delivered by means of pharmacogenomics and fastidious 
TDM management in the future. In the meantime, there 
is an international consensus for the use of combination 
antifungal therapy for the major opportunistic infections 
in the specific settings outlined in this article.
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